21
total announcements
ANUHPHR.BO · 15 min delayed
Key Stats · Yahoo Finance · as of 10 Nov 2026
Market Cap
₹834 Cr
P/E (TTM)
19.0
P/E (Forward)
6.8
EPS (TTM)
₹4.39
52W Low
₹66.72
52W High
₹99.50
Dividend Yield
1.82%
Price / Book
2.3
Return on Equity
13.91%
Debt / Equity
5.4
Revenue (TTM)
₹778 Cr
Gross Margin
23.17%
Operating Margin
8.13%
Anuh Pharma Ltd
Anuh Pharma Ltd has published unaudited financial results for the quarter and half year ended 30th September, 2026, in the Financial Express and Mumbai Lakshdeep newspapers.
Anuh Pharma Ltd
Anuh Pharma Ltd has received a request for withdrawal of an application for reclassification of shareholding from 'Promoter & Promoter Group' to 'Public Category'. The request was submitted by Mrs. Nina Vijay Shah, a shareholder belonging to the Promoter Group, who has decided to withdraw her request for reclassification.
Anuh Pharma Ltd
Anuh Pharma Ltd has announced its unaudited financial results for the quarter and half year ended 30th September, 2026, showing revenue from operations of Rs. 18,524.14 lakhs and profit after tax of Rs. 1,121.31 lakhs.
Anuh Pharma Ltd
Anuh Pharma Ltd has announced its unaudited financial results for the quarter and half year ended 30th September, 2026, along with a request from a shareholder to withdraw their application for reclassification from 'Promoter and Promoter Group' to 'Public Category'.
Anuh Pharma Ltd
Anuh Pharma Ltd has scheduled a Board Meeting on 30th October, 2026 to consider and approve Unaudited Financial Results for the quarter and half year ended 30th September, 2026.
Anuh Pharma Ltd
Anuh Pharma Ltd has received the possession of a manufacturing facility from Vanquest Pharma Private Limited, as per an Asset Transfer Agreement. This is in line with their initial intimation dated 16th October, 2026.
Anuh Pharma Ltd
Anuh Pharma Ltd has signed an Asset Transfer Agreement to purchase a manufacturing facility from Vanquest Pharma Private Limited, expected to increase production by 525 MTPA and strengthen the company's market presence.
Anuh Pharma Ltd
Anuh Pharma Ltd has approved investment in manufacturing assets for expansion and proposed availing a loan of up to ₹ 75 crs for the same. The Board of Directors met on 13th October, 2026, and approved the proposals. The details of the transaction will be disclosed as per the SEBI (LODR) Regulations, 2015.
Anuh Pharma Ltd
Anuh Pharma Ltd's board has approved investment in manufacturing assets for expansion and proposed a loan of up to ₹ 75 crs for the purchase of these assets to expand production capacity.
Anuh Pharma Ltd
Anuh Pharma Ltd has received a compliance certificate from Bigshare Services Private Limited, its Registrar and Share Transfer Agent, pursuant to Regulation 74(5) of SEBI (Depositories and Participants) Regulation, 2018, for the quarter ended 30th September, 2026.
Anuh Pharma Ltd
Anuh Pharma Ltd has announced the closure of its trading window for insiders and designated persons from October 1, 2026, until 48 hours after the declaration of unaudited financial results for the quarter and half year ended September 30, 2026.
Anuh Pharma Ltd
Anuh Pharma Ltd, a leading API manufacturer, has released its Q1 FY 2026-27 investor presentation, showcasing a confident start to the fiscal year with profit growth exceeding revenue growth. The company attributes this to its shift towards higher-value products in regulated markets, a richer product mix, disciplined cost control, and better throughput from existing assets.
Anuh Pharma Ltd
Anuh Pharma Ltd has announced the reappointment of two non-executive directors, Bipin Nemchand Shah and Arun Lalchand Todarwal, and the revision of remuneration for two joint managing directors, Ritesh B. Shah and Vivek Shah. The company has also adopted new Memorandum of Association and Articles of Association, subject to shareholder approval.
Anuh Pharma Ltd
Anuh Pharma Ltd has submitted the Scrutinizer Report and Voting Results for its 66th Annual General Meeting, which was held on August 12, 2026. The meeting saw a total of 45 shareholders attending through video conferencing, with 17 promoters and 28 public shareholders participating. The company has also announced a dividend of Rs. 1.50 per equity share for the financial year 2025-26. The resolutions for the appointment of directors were also passed with significant majority.
Anuh Pharma Ltd
Anuh Pharma Ltd held its 66th Annual General Meeting on August 12, 2026, through video conferencing, where resolutions related to financial statements, dividend, director appointments, and remuneration were passed.
Anuh Pharma Ltd
Anuh Pharma Ltd has published unaudited financial results for the quarter ended June 30, 2026, in the Financial Express and Mumbai Lakshdeep newspapers, as required by Regulation 47 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Anuh Pharma Ltd
Anuh Pharma Ltd has announced the adoption of a revised policy on related party transactions, which is available on the company's website. The board of directors also approved the unaudited financial results for the quarter ended 30th June, 2026, and the requests from shareholders to withdraw their application for reclassification.
Anuh Pharma Ltd
Anuh Pharma Ltd has received a request for withdrawal of an application for reclassification of shareholding from 'Promoter & Promoter Group' to 'Public Category'. The request was submitted by three shareholders, who will continue to remain part of the Promoter Group.
Anuh Pharma Ltd
Anuh Pharma Ltd has announced its unaudited financial results for the quarter ended June 30, 2026, showing a profit of Rs. 1,142.49 lakhs and a revenue of Rs. 19,688.71 lakhs.
Anuh Pharma Ltd
Anuh Pharma Ltd's board meeting on August 7, 2026, approved the unaudited financial results for the quarter ended June 30, 2026, along with a limited review report. The company also received requests from shareholders to withdraw their application for reclassification, which was approved. Additionally, the board adopted a revised policy on related party transactions.